Community project funding/congressionally directed spending - construction - the focus of this grant application is an expansion of the life sciences capability at mriglobal's owned headquarters…

Community project funding/congressionally directed spending - construction - the focus of this grant application is an expansion of the life sciences capability at mriglobal's owned headquarters facility located at 425 DR. Martin luther king JR. Boulevard. Mriglobal's headquarters is a modern 225,000 SQ. FT. Facility that includes 60,000 SQ. FT. Of scientific laboratory space plus administrative offices and other capabilities supporting mriglobal's mission to use science and technology to create solutions for a safer, healthier, more sustainable world. This life sciences capability expansion project is intended to advance mriglobal's ability to support human health through research projects conducted for multiple NIH organizations, including NCI, niaid, ninds, niehs, and ncats, as well ASL the CDC and FDA. The proposed investment will provide funding to purchase scientific laboratory equipment and laboratory infrastructure to expand our offerings to current and prospective customers. This investment will advance r & d in new and investigational drugs and new technologies in medical treatments. Mriglobal is a 501C3 not-for-profit organization that conducts more than $110M/year of research for federal and commercial customers. Our federal research efforts support initiatives for the department of health and human services and the department of defense. Mriglobal is committed to remaining well-positioned to advance the health and safety of our world. Mriglobal's growth ambition to double its impact over the next decade will positively impact the regional kansas city economy by growing the number of high paying jobs and services, maintaining our leadership as a strong and active corporate citizen, and continuing to support kansas city's science, technology, engineering and math education programs and workforce development. Mriglobal was optimally poised to respond to the priority needs of the global covid-19 crisis. We supported safety and efficacy evaluation of candidate treatments for covid-19, testing of disinfectant technologies, mask evaluations, development/application of covid-19 diagnostic testing, developing back-to-work/school safety plans for academic institutions and deploying several mobile laboratories and containment units to pandemic response efforts. This investment will allow mriglobal to continue to address these urgent national and global health programs without a lapse of support to other federal clients with priority needs in areas of warfighter protection, biosurveillance for pathogens, research to support advancement of therapeutics and vaccines for cancer, neurological health and other infectious diseases.